- Home
- ABP vs THAR Comparison
ABP vs THAR Comparison
Compare ABP & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABP
- THAR
- Stock Information
- Founded
- ABP 2004
- THAR 2017
- Country
- ABP United States
- THAR United States
- Employees
- ABP N/A
- THAR N/A
- Industry
- ABP Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- ABP Health Care
- THAR Health Care
- Exchange
- ABP Nasdaq
- THAR Nasdaq
- Market Cap
- ABP 17.2M
- THAR 16.8M
- IPO Year
- ABP N/A
- THAR 2022
- Fundamental
- Price
- ABP $0.19
- THAR $3.18
- Analyst Decision
- ABP Strong Buy
- THAR Strong Buy
- Analyst Count
- ABP 1
- THAR 1
- Target Price
- ABP $4.00
- THAR $17.00
- AVG Volume (30 Days)
- ABP 5.0M
- THAR 644.6K
- Earning Date
- ABP 11-18-2025
- THAR 11-06-2025
- Dividend Yield
- ABP N/A
- THAR N/A
- EPS Growth
- ABP N/A
- THAR N/A
- EPS
- ABP N/A
- THAR N/A
- Revenue
- ABP $183,000.00
- THAR N/A
- Revenue This Year
- ABP N/A
- THAR N/A
- Revenue Next Year
- ABP N/A
- THAR N/A
- P/E Ratio
- ABP N/A
- THAR N/A
- Revenue Growth
- ABP 154.17
- THAR N/A
- 52 Week Low
- ABP $0.15
- THAR $0.95
- 52 Week High
- ABP $11.19
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- ABP 43.91
- THAR 49.85
- Support Level
- ABP $0.19
- THAR $2.88
- Resistance Level
- ABP $0.21
- THAR $3.17
- Average True Range (ATR)
- ABP 0.02
- THAR 0.31
- MACD
- ABP -0.00
- THAR -0.00
- Stochastic Oscillator
- ABP 14.12
- THAR 40.22
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.